Please wait while we open this resource.
K
Clinical reviews
COMBINING GLUCAGON - LIKE PEPTIDE - 1 RECEPTOR AGONISTS (GLP - 1RAS) AND SODIUM - GLUCOSE COTRANSPORTER - 2 INHIBITORS (SGLT2IS) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Pierre Gourdy, Patrice Darmon, François Dievart, Jean‑Michel Halimi, Bruno Guerci
PDF202314 pages1.0 MB
The article presents evidence supporting the combined use of GLP-1RAs and SGLT2is in patients with T2DM, particularly those with established atherosclerotic cardiovascular disease or multiple risk factors. It emphasizes the cardiovascular protective effects of these therapies and their potential to improve renal outcomes. The review also addresses the safety profile of these medications, including common adverse effects and their management.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
ADA Consensus Report: MASLD in People With Diabetes
Same clinical topic · Endocrinology
2025 ADA Diabetes Care Standards Updates
Same clinical topic · Endocrinology
METFORMIN―MECHANISMS OF ITS GLYCEMIA-REDUCING EFFECT
Same clinical topic · Endocrinology
SYNDROME OF INAPPROPRIATE ANTIDIURESIS: FROM PATHOPHYSIOLOGY TO MANAGEMENT
Same clinical topic · Endocrinology
GLYCEMIC EMERGENCIES
Same clinical topic · Endocrinology
DIAGNOSIS AND MANAGEMENT OF CENTRAL DIABETES INSIPIDUS IN ADULTS
Same clinical topic · Endocrinology
ANTI-OBESITY DRUGS: COMPREHENSIVE REVIEW AND EMERGING THERAPIES
Same clinical topic · Endocrinology
DRUG DELIVERY SYSTEMS FOR THYROID DISEASE TREATMENT: A MINI REVIEW ON CURRENT THERAPIES AND ALTERNATIVE APPROACHES
Same clinical topic · Endocrinology
OTHER BENEFITS OF CONTROLLING CARBOHYDRATES
Same clinical topic · Endocrinology